News from antisense therapeutics limited

Apr 01, 2014, 09:45 ET

ATL1102 for MS - Toxicology Study Main Findings

Antisense Therapeutics Limited ("ANP" or the "Company") is pleased to advise that results from a chronic toxicity study in monkeys indicate that...

Mar 21, 2014, 10:00 ET

ATL1103 Acromegaly Phase II Trial Recruitment Completed

Antisense Therapeutics Limited ("ANP") is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of...

Mar 17, 2014, 19:20 ET

ATL1102 for Stem Cell Mobilisation Trial Commencement

Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of...

Jan 07, 2014, 17:49 ET

Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014

 Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that it has been selected to present at the Biotech Showcase 2014...

Dec 23, 2013, 07:15 ET
Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial.  (PRNewsFoto/Antisense Therapeutics Limited)

Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial

 Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that positive results have been achieved from the interim...

Aug 28, 2013, 07:30 ET

ANP to present at and attend major US investment, partnering and industry conferences

 Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been...

Jan 18, 2006, 00:00 ET

Antisense Therapeutics Receives Approval to Restart Phase IIa Trial of ATL1102 for Patients with Multiple Sclerosis

MELBOURNE, Australia, Jan. 18 /PRNewswire-FirstCall/ -- Antisense Therapeutics Limited (ASX: ANP) has received approval from the Ethics...

Jan 13, 2005, 00:00 ET

Antisense Therapeutics Announces Launch of Level 1 American Depository Receipt Program

MELBOURNE, Australia, Jan. 13 /PRNewswire-FirstCall/ -- Antisense Therapeutics Limited (ASX: ANP) today announced that its Level One American...

Nov 18, 2004, 00:00 ET

Antisense Therapeutics to Initiate Proof of Concept Clinical Trial for its ATL1101 Compound for Psoriasis

MELBOURNE, Australia, Nov. 18 /PRNewswire-FirstCall/ -- Antisense Therapeutics Limited (ASX: ANP) announced that it will conduct a "proof of...

Oct 07, 2004, 01:00 ET

Antisense Therapeutics to Establish Level 1 American Depository Receipt Program

MELBOURNE, Australia, Oct. 7 /PRNewswire/ -- Antisense Therapeutics Limited (ASX: ANP) announced that it has accepted a proposal from The Bank...

Jun 08, 2004, 01:00 ET

Antisense Therapeutics Limited and Isis Pharmaceuticals Announce Positive Results From a Phase 1 Trial of ATL-1102 for Multiple Sclerosis

MELBOURNE, Australia and CARLSBAD, Calif., June 8 /PRNewswire-FirstCall/ -- Antisense Therapeutics Limited (ASX: ANP) and Isis Pharmaceuticals,...

Jun 08, 2004, 01:00 ET

Antisense Therapeutics Limited and Isis Pharmaceuticals Announce Positive Results From A Phase 1 Trial Of ATL-1102 for Multiple Sclerosis

MELBOURNE, Australia and CARLSBAD, Calif., June 8 /PRNewswire-FirstCall/ - - Antisense Therapeutics Limited (ASX: ANP) and Isis Pharmaceuticals,...

Apr 22, 2004, 01:00 ET

Antisense Therapeutics CEO Mark Diamond Interviewed by Wall Street Reporter

VICTORIA, Australia, April 22 /PRNewswire/ -- Antisense Therapeutics Limited (ASX: ANP), a biopharmaceutical company, announced that CEO Mark...

Feb 02, 2004, 00:00 ET

Antisense Therapeutics Presents Preliminary ATL1102 Phase I Results At Neurosciences Conference

VICTORIA, Australia, Feb. 2 /PRNewswire/ -- Antisense Therapeutics Limited (ASX: ANP), a biopharmaceutical company today announced that...

Jan 13, 2004, 00:00 ET

Antisense Therapeutics CEO Mark Diamond to be Featured Guest on Biotech Today Radio Program

VICTORIA, Australia, Jan. 13 /PRNewswire/ -- Antisense Therapeutics Limited (ASX: ANP), a biopharmaceutical company today announced that CEO...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Analysts Review